TY - JOUR
T1 - Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer
AU - Rodenhuis, Sjoerd
AU - van der Wall, Elsken
AU - ten Bokkel Huinink, Willem W.
AU - Schornagel, Jan H.
AU - Richel, Dick J.
AU - Tom Vlasveld, L.
PY - 1995
Y1 - 1995
N2 - Eleven patients with germ cell cancer relapsing from a complete remission and 7 patients with refractory germ cell cancer and/or an unresectable partial remission received salvage chemotherapy with one to two courses of carboplatin (800 mg/m2) and etoposide (500 mg/m2 on days 1, 3, and 5), followed b either one or two courses of carboplatin (1600 mg/m2), cyclophosphamide (6 g/d2), and thiotepa (480 mg/m2) divided over 4 days with autologous bone marrow transplantation andlor peripheral stem cell support. Eight of 11 relapsing patients (73% were salvaged (with a follow-up of 21+ to 56+ months), but only 1 of the 7 refractory patients survived (34+ months). The high-dose carboplatin-based salvage regimen is feasible and deserves further evaluation in patients relapsing from a complete remission. Even more intensive treatment strategies may be required to salvage patients who are refractory to standard doses of platinating agents.
AB - Eleven patients with germ cell cancer relapsing from a complete remission and 7 patients with refractory germ cell cancer and/or an unresectable partial remission received salvage chemotherapy with one to two courses of carboplatin (800 mg/m2) and etoposide (500 mg/m2 on days 1, 3, and 5), followed b either one or two courses of carboplatin (1600 mg/m2), cyclophosphamide (6 g/d2), and thiotepa (480 mg/m2) divided over 4 days with autologous bone marrow transplantation andlor peripheral stem cell support. Eight of 11 relapsing patients (73% were salvaged (with a follow-up of 21+ to 56+ months), but only 1 of the 7 refractory patients survived (34+ months). The high-dose carboplatin-based salvage regimen is feasible and deserves further evaluation in patients relapsing from a complete remission. Even more intensive treatment strategies may be required to salvage patients who are refractory to standard doses of platinating agents.
UR - http://www.scopus.com/inward/record.url?scp=0029151697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029151697&partnerID=8YFLogxK
U2 - 10.3109/07357909509031915
DO - 10.3109/07357909509031915
M3 - Article
C2 - 7627721
AN - SCOPUS:0029151697
SN - 0735-7907
VL - 13
SP - 355
EP - 362
JO - Cancer Investigation
JF - Cancer Investigation
IS - 4
ER -